Zevra Therapeutics (ZVRA) Cost of Revenue (2019 - 2026)

Zevra Therapeutics' Cost of Revenue history runs 7 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• Quarterly Cost of Revenue rose 41.04% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (up 98.37% YoY) and the FY2025 annual result came in at $16.5 million, up 122.22% from the prior year.
• Cost of Revenue was $1.9 million for Q1 2026 at Zevra Therapeutics, up from $1.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $12.4 million in Q2 2025 and bottomed at $8000.0 in Q1 2022.
• A 5-year average of $1.7 million and a median of $1.2 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue slumped 98.0% — and 2023, when it surged 3285.0%.
• Zevra Therapeutics' Cost of Revenue stood at $92000.0 in 2022, then soared by 1233.7% to $1.2 million in 2023, then increased by 11.33% to $1.4 million in 2024, then increased by 11.27% to $1.5 million in 2025, then increased by 24.8% to $1.9 million in 2026.
• Business Quant data shows ZVRA's Cost of Revenue at $1.9 million in Q1 2026, $1.5 million in Q4 2025, and $1.2 million in Q3 2025.